Indications
Lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.
Composition
- Active substance
- lixisenatide
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Lyxumia
- Active substance
- lixisenatide
- ATC code
- A10BJ03
- Therapeutic area
- Diabetes Mellitus, Type 2
- Marketing authorisation holder
- Sanofi Winthrop Industrie